TWAPF Stock Chart & Stats
$25.33
$0.00(0.00%)
At close: 4:00 PM EST
$25.33
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$20.72 - $28.05
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
$1.24B
Enterprise Value$378.59K
Total Cash (Recent Filing)$45.31B
Total Debt (Recent Filing)$226.74B
Price to Earnings (P/E)38.6
Beta0.42
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)106.65
Shares Outstanding51,516,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$34.18Price Target Upside34.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.76
Revenue Forecast (FY)$1.87B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line expansion across 2021–2026 signals the company’s generics portfolio is capturing demand and new product launches. Durable revenue momentum supports scale advantages in manufacturing and distribution, enabling reinvestment in pipeline and supply reliability over the next 2–6 months.
Improving Cash GenerationThe shift to positive operating and free cash flow in 2026 marks a structural inflection that enhances financial flexibility. Improved internal cash generation reduces reliance on external financing, enabling sustained capex, working capital management, and potential debt reduction over the medium term.
Broad Generics PortfolioA diversified generics product mix across therapeutic areas gives durable revenue diversification and resilience to individual molecule patent expiries. Strong presence in Japan’s regulated reimbursement system supports repeat demand and steady volumes, underpinning medium-term market share retention.
Bears Say
Elevated LeverageA debt-heavy capital structure reduces financial flexibility and raises refinancing and interest-rate risk. Elevated leverage constrains the company’s ability to absorb shocks or fund growth without external capital, increasing vulnerability if earnings or cash flow weaken again in the coming months.
Profitability VolatilityLarge swings in net income indicate earnings are sensitive to non-operating items, pricing or cost pressures. Volatile profitability undermines predictability of returns and makes planning for sustained margin expansion or consistent dividend/capex policy more difficult over the medium term.
Inconsistent Cash Flow HistoryThe recent positive FCF is encouraging, but a history of negative free cash flow shows cash generation can lapse when spending or working capital rises. This inconsistency increases financing reliance during weaker periods and elevates execution risk for sustained deleveraging or reinvestment.
Towa Pharmaceutical Co News
TWAPF FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was $20.72 and its highest was $28.05 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is $1.24B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 10 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on May 14, 2026. The company reported -$1.469 earnings per share for the quarter, missing the consensus estimate of $0.66 by -$2.129.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of $0.244 which represents an annual dividend yield of 3.02%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of -$1.469 in its last earnings report, missing expectations of $0.66. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in TWAPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
TWAPF Stock 12 Month Forecast
Average Price Target
$34.18
▲(34.93% Upside)
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Ownership Overview
―
Insiders
6.44% Mutual Funds
― Other Institutional Investors
89.43% Public Companies and
Individual Investors